{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"title":"3 or more"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Participants are recorded under the treatment they were receiving at the time the dose reduction was reported.","groups":[{"description":"Participants received 4 overencapsulated capsules of sunitinib (either in Period 1 or Period 2), each containing 12.5 mg of sunitinib, OD orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.","id":"OG000","title":"Sunitinib"},{"description":"Participants received 4 overencapsulated tablets of pazopanib (either in Period 1 or Period 2), each containing 200 mg of pazopanib, OD orally for 10 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.","id":"OG001","title":"Pazopanib"}],"paramType":"NUMBER","populationDescription":"Safety-Randomized Study Population. Only those participants who had an dose reduction were evaluated.","reportingStatus":"POSTED","timeFrame":"End of second treatment period (maximum of 22 weeks)","title":"Number of Participants With the Indicated Number of Dose Reductions","type":"SECONDARY","unitOfMeasure":"participants"}